Key result
Among older adults with cardiovascular disease, 95% were exposed to polypharmacy, 69% to hyper-polypharmacy, and 77.5% had at least one severe potential drug-drug interaction.
Why the study?
Polypharmacy remains a concern in older adults that increases the risk of potential drug-drug interactions and adverse health outcomes, warranting assessment among older adults with CVD.
Population
404 older adults (age ≥ 65 years) with CVD admitted to a cardiology service
Design
Retrospective chart review
Authors
Loading...
Warrants routine medication review in older CVD patients; leaves open whether deprescribing improves outcomes in prospective trials.
Observational (n=404)
No
Polypharmacy and severe potential drug-drug interactions are highly prevalent among older adults with cardiovascular disease, highlighting the need for vigilant medication review.
Sheikh‐Taha et al. (2021) conducted an observational in Cardiovascular disease (n=404). Polypharmacy was evaluated on Prevalence of polypharmacy (≥5 concomitant medications). Among older adults with cardiovascular disease, 95% were exposed to polypharmacy, 69% to hyper-polypharmacy, and 77.5% had at least one severe potential drug-drug interaction.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: